Method for purifying acidic human milk oligosaccharides from fermentation broth
Patent Information
- Application Number
- CN202180071217.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-10-30
- Filing Date
- 2021-10-29
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-10-29
Abstract
Description
[0001] This invention relates to a method for purifying acidic human milk oligosaccharides (HMOs).
[0002] Breast milk contains various oligosaccharides (HMOs), which are important for the healthy development of infants. Many HMOs play an important role in the development of a healthy gut microbiome.
[0003] Many HMOs exist; the most abundant HMOs in breast milk are fucoidyl lactoses such as 2'-fucosylvose (2'-FL) and 3'-fucosylvose (3'-FL), sialylated lactoses such as 3'-sialylvose (3'-SL) and 6'-sialylvose (6'-SL), and tetrasaccharides such as lactose-N-tetrasaccharide (LNT) and lactose-N-neotetrasaccharide (LNnT).
[0004] 2'-FL, 3-FL, LNT, and LNnT are neutral; in a sense, they are uncharged.
[0005] Neutral HMOs can be purified relatively easily from the fermentation broth that produces them. Anion exchange chromatography and cation exchange chromatography are used in this purification to remove charged substances.
[0006] For example, WO 2019 / 063757 discloses a method for purifying fucosylated HMOs, which includes ultrafiltration of fermentation broth, cation exchange using a strong cation exchange resin, and the use of OH- - The process involves anion exchange using a weak anion exchange resin and finally adsorption of neutral components other than fucosylated HMO using a highly porous weak cation exchange resin.
[0007] Sialinated HMOs such as 3'-sialyl lactose (3'-SL) and 6'-sialyl lactose (6'-SL) are acidic / negatively charged and are typically prepared in their sodium form. This negative charge hinders the application of purification techniques for the aforementioned neutral HMOs because the negatively charged HMOs will compete with other anions when bound to anion exchange resins, resulting in poor separation.
[0008] WO 2009 / 113861 discloses the separation of sialylated oligosaccharides from skim milk streams, preferably protein-free milk streams, by subjecting the milk stream—after optional softening and nanofiltration—to (i) a cation exchange step, (ii) an anion exchange step using an anion exchange resin in free base form and having a water content of 30%-48%, (iii) binding the oligosaccharides to a microporous or gel-type anion exchange resin with a water content >45% and preferably also in free base form, and (iv) eluting the oligosaccharides from the resin using an acidic salt solution.
[0009] WO 2010 / 106320 discloses a method for separating and purifying 3'-SL from whey by demineralizing the whey using a series of two anion exchange resins and two cation exchange resins, followed by contacting the demineralized whey with a strongly acidic cation exchange resin and a weakly basic anion exchange resin. 3'-SL binds to the weak anion exchange resin and is subsequently eluted therefrom.
[0010] WO 2017 / 152918 discloses a method for separating sialylated oligosaccharides from fermentation broth by: (i) ultrafiltration, (ii) nanofiltration, (iii) optional activated carbon treatment, and (iv) treatment with a strong anion or strong cation exchange resin. Negatively charged materials (including sialylated oligosaccharides) are bound to a strong anion exchange resin. In one embodiment, the sialylated oligosaccharides are recovered from the anion exchange resin by elution with an aqueous solution of acid or salt. In another embodiment, from H-... + The product is eluted in a strong cation exchange resin and then neutralized with NaOH to produce the sodium salt of the oligosaccharide.
[0011] WO 2019 / 229118 discloses a method for purifying sialic acid lactose from other carbohydrates in fermentation broth by removing cell clumps using at least one, but preferably two, ultrafiltration steps, followed by purification with H2O. + Cation exchange resins in the form of Cl - The resulting solution was treated with a strong anion exchange resin, and carbohydrates were removed from the solution by filtration through two membranes: one with a molecular weight cutoff of 300-500 Da and the other with a molecular weight cutoff of 600-800 Da. After treatment with a cation exchange resin, the solution was neutralized to pH 7 with NaOH. After treatment with anion exchange resin, the solution was again neutralized to pH 7. Thus, a significant amount of salt was introduced, which must then be removed by electrodialysis.
[0012] WO 2019 / 043029 discloses the purification of sialyl lactose from other carbohydrates in fermentation broth by separating biomass from the fermentation broth via centrifugation, microfiltration, or ultrafiltration, using H-type... + A strong cation exchange resin is used to remove cations, raising the pH of the resulting eluent containing sialic acid lactose to 7, and then using a Cl-type eluent. - Strong anion exchange resins are used to remove anionic impurities, and compounds with molecular weights lower than that of sialic lactose are removed by nanofiltration or percolation.
[0013] Furthermore, the method involves neutralizing the saliva lactose to pH 7 with NaOH between two ion exchange treatments, thereby generating a large amount of salt that must be removed.
[0014] EP 3 456 836 A1 discloses two methods for separating sialic lactose from fermentation broth. Both methods include an ion exchange step, followed by ultrafiltration, nanofiltration, and / or activated carbon treatment. According to the first method, these ion exchange steps begin with the use of Cl-... - Anion exchange using a strong anion exchange resin in the form of H+, followed by the use of H+. + Or Na + The cation exchange step of the cation exchange resin is described. An advantage disclosed in this embodiment is that no neutralization is required between the two ion exchange steps.
[0015] However, a drawback of this example is that the anion exchange step may raise the pH of the solution, which could cause any salt (like Ca salts) to precipitate. Therefore, it is preferable to start with cation exchange rather than anion exchange to remove metal ions before they may precipitate.
[0016] The second method begins with the use of H... + Or Na + The cation exchange of the resin in the form of Cl- followed by the use of Cl- - Anion exchange using strong anion exchange resins in the form of H+. + For cation exchange resins in this form, neutralization with NaOH is required before delivery to strong anion exchange resins to form a sodium salt of sialyl lactose. Otherwise, sialyl lactose will bind to the strong anion exchange resin. This neutralization necessitates the introduction of a salt.
[0017] It has been found that by introducing less salt and / or eliminating the neutralization step between ion exchange steps, it is possible to separate and purify acidic HMOs from fermentation broth to a satisfactory degree using ion exchange methods. Therefore, the number and / or extent of desalting operations (such as electrodialysis) can be reduced, or even avoided altogether.
[0018] Therefore, the present invention relates to a method for purifying acidic human milk oligosaccharides (HMOs) from fermentation broth, the method comprising the following steps:
[0019] (i) Separate the biomass from the fermentation broth to provide a crude solution;
[0020] (ii) subject the crude solution to use to form H₂ + Cation exchange of cation exchange materials in the form of cation exchange, thereby obtaining solutions with a pH range of 1-3;
[0021] (iii) subjecting the solution with a pH range of 1-3 to a pH of Cl for use. - Anion exchange using a weakly basic anion exchange material to obtain a solution with a pH in the range of 1.5-5.5, preferably 1.5-4;
[0022] (iv) subject the solution with a pH in the range of 1.5-5.5, preferably 1.5-4, to adsorption using an adsorbent material in order to remove neutral organic compounds;
[0023] (v) Optionally, adjust the pH of the already adsorbed solution to a value in the range of 5-6;
[0024] (vi) Optionally, the solution is subjected to anion exchange using an anion exchange resin, thereby binding the acidic human milk oligosaccharide to the resin, and then the acidic human milk oligosaccharide is eluted from the resin using a salt solution. This optional step is performed between steps (iii) and (iv) or between steps (iv) and (v).
[0025] Thus, a purified solution containing the acidic human milk oligosaccharide is obtained.
[0026] Examples of acidic human milk oligosaccharides that can be purified by this method include sialylated oligosaccharides, preferably selected from the group consisting of: 6'-sialylose (6'-SL), 3'-sialylose (3'-SL), disialialactolose-N-tetrasaccharide, 3'-sialyl-3-fucosylationlose, sialylose-N-tetrasaccharide, fucosylsialylose-N-neohexose, di-fucosylsialylose-N-hexasaccharide, sialylose-N-tetrasaccharide a, sialylose-N-tetrasaccharide b, fucosylsialylose-N-hexasaccharide, and 3'-fucosylsialylose-N-tetrasaccharide. More preferably, the HMOs to be purified by this method are 6'-sialylactose (6'-SL), 3'-sialylactose (3'-SL), disialialactol-N-tetrasaccharide, 3'-sialic acid-3-fucosylated lactose, and sialyl-N-tetrasaccharide. Most preferably, the method of the present invention is used to purify 6'-sialylactose (6'-SL) or 3'-sialylactose (3'-SL).
[0027] During treatment with the ion exchange material in steps (ii) and (iii), the acidic HMO remains in solution while other charged components are effectively removed. The acidic HMO will not—or only to a limited extent—bind with the weakly basic anion exchange material used in step (iii).
[0028] It is inferred that due to the low pH conditions of the solution underwent with the weakly basic anion exchange resin in step (iii), the HMO becomes protonated and thus exhibits neutral HMO. On the other hand, other negatively charged components in the solution will bind with the weakly basic anion exchange material and are therefore removed from the solution.
[0029] Fermentation broth typically contains microorganisms used to produce HMOs or their residues, as well as nutrients used by these microorganisms. Residual carbon sources from which HMOs are produced may also be present. Furthermore, one or more byproducts produced by the microorganisms may be present.
[0030] The fermentation production of HMOs can be carried out based on known methods for microbial production of oligosaccharides, such as those described in the prior art mentioned above or cited herein. Lactose is preferably used as a carbon source, which is converted into HMOs by microorganisms in the fermentation broth.
[0031] Separating biomass from the liquid phase (step (i)) can be accomplished in a manner known per se for the type of fermentation broth already used for HMO production. Purification and / or filtration can be used. The fermentation broth can be subjected to a degassing step before or during step (i). Suitable degassing steps are generally known in the art. The advantage of degassing is that it reduces the risk of bubble formation during subsequent steps. Such bubbles can adversely affect the flow of the solution through the packed column, and in the case of using loose beads, gas formation can lead to the floating of adsorbent or ion exchange materials.
[0032] The crude solution obtained through separation step (i) can be subjected to microfiltration (MF) and / or ultrafiltration (UF). MF is typically performed using membranes with pore sizes less than 1 μm, preferably about 0.1-0.2 μm. MF is particularly suitable for removing cellular material (intact cells, fragments thereof) and other supramolecular debris. MF can be performed at approximately ambient temperature. Typically, the temperature is in the range of 20°C to 75°C. Preferably, MF is performed at a temperature of at least 30°C, more preferably in the range of 35°C to 70°C. Relatively high temperatures have been found to improve HMO yield. Temperatures in the range of about 40°C to 50°C, such as about 45°C, or temperatures in the range of about 60°C to 70°C, such as about 65°C, are particularly advantageous. Without being bound by theory, the inventors believe that the secretion from biomass to the liquid phase is improved at higher temperatures. Furthermore, higher temperatures, especially about 60°C to 70°C, are beneficial for achieving a higher concentration factor of cellular material during microfiltration, which has a positive impact on HMO yield.
[0033] Ultrafiltration is particularly suitable for removing proteins, DNA, and / or endotoxins from permeate. Heat treatment is used to modify proteins, for example, denature them, thereby making them less permeable to the UF membrane. The UF membrane preferably has a retention cutoff of 5 kDa or less, particularly about 3 kDa or less. The retention cutoff is typically at least about 1 kDa.
[0034] In a preferred embodiment, the MF permeate is cooled to a temperature below 20°C, more preferably below 15°C, and most preferably in the range of 8°C-12°C before undergoing ultrafiltration.
[0035] To improve the recovery rate of HMO in the fermentation broth, MF and / or UF can be applied together with percolation.
[0036] Following the optional filtration steps discussed above, the crude solution is then treated with: a cation exchange material (step (ii)); a weakly basic anion exchange material (step (iii)); and an adsorbent material (step (iv)).
[0037] The terms 'weak' ion exchange and 'strong' ion exchange are generally known in the art. Once the ion exchanger reaches equilibrium, a strong ion exchanger will not significantly release the charge on its matrix and can therefore be used over a wide pH range—typically from strongly acidic to strongly basic pH. Strong anion exchange resins are typically characterized by the presence of quaternary ammonium groups.
[0038] Weak ion exchangers have a more specific pH range in which they maintain their charge, typically acidic to to neutral pH in the case of weak anion exchangers and basic to to neutral pH in the case of weak cation exchangers. Weak anion exchangers are generally characterized by the absence of quaternary ammonium groups. A common weak anion exchanger group is the tertiary amine group.
[0039] Ion exchange materials can be provided as membranes, as charge-modified depth filters in packed columns, or as suspension or fluidizing materials. Ion exchange materials typically comprise a matrix with fixed functional groups (cations for anion exchange materials, anions for cation exchange materials). Examples of suitable matrices are fibrous gels, microcrystalline gels, or beaded gels. These can be made from, for example, polysaccharide-based materials (e.g., agarose, agarose gel, cellulose), silica-based materials, or organic (co)polymers (e.g., polyacrylamide, polystyrene). Functional groups can be introduced through derivatization.
[0040] Ion exchange materials can be employed in a manner known to the specific material of interest (e.g., as specified by the supplier). Strong ion exchangers have the advantage of capturing ions over a wide pH range. Weak ion exchangers have the advantage of being easily regenerated: regeneration requires fewer chemicals. The ion exchange materials used in the methods of this invention should meet food-grade standards—i.e., permitted for use in the production of food ingredients—and preferably also meet various religious food standards (e.g., halal and kosher).
[0041] The cation exchange material in step (ii) serves as a cation exchange agent, i.e., for removing positively charged components. Cation exchange step (ii) preferably includes treatment with a strong cation exchange material. Preferably, the cation exchange material is a strong acid cation exchange material selected from the group consisting of: styrene-divinylbenzene cation exchange resin, more preferably gel-type styrene-divinylbenzene cation exchange resin. Using H... + Cation exchange is performed using a cation exchange material in the form of (step (ii)). In a preferred embodiment, the cation exchange material contains sulfonic acid functional groups. Most preferably, the cation exchange material is a strong acid cation exchange resin having a styrene / divinylbenzene gel-type matrix and sulfonic acid functional groups.
[0042] After treatment with a cation exchange material, the solution containing HMO will have a pH in the range of 1-3. The solution is then subjected to anion exchange material (step (iii)) without raising the pH or introducing additional ions into the solution. As mentioned above, due to the low pH conditions during anion exchange, the HMO is protonated and thus behaves as a neutral HMO.
[0043] The weakly basic anion exchange material in step (iii) is used as an anion exchanger to remove negatively charged components, and more specifically, to remove polyvalent ions such as phosphate and sulfate. The anion exchange material is Cl- - This form means that the anion exchange material contains Cl. - Counterions, optionally with other anions (e.g., OH-) - The combination is preferably in which at least 90% of the anions are Cl. - Anions. Two types of anion exchange materials can also be used, one of which is Cl-... - Anion exchange materials in one form and another in another form (e.g., OH-) - This is an anion exchange material. During the treatment of a filtered solution with this material, the strong anions in the solution will bind to the material, while most of the acidic HMO remains in the solution.
[0044] The anion exchange material is a weakly basic anion exchange material, preferably selected from the group consisting of: styrene-divinylbenzene anion exchange resin and cross-linked acrylic anion exchange resin, more preferably gel-type styrene-divinylbenzene anion exchange resin and gel-type cross-linked acrylic anion exchange resin. The resin preferably has tertiary amine functional groups, more preferably dimethylamine functional groups. The anion exchange material exhibits Cl... - form.
[0045] When protonated HMO flows through the column, strong anion exchange resins will capture protonated HMO, which is beneficial for organic acid impurities, while weak anion exchange resins will preferentially capture anion impurities.
[0046] Anion exchange resins can be regenerated with HCl, which can then be used as a regenerator for cation exchange resins.
[0047] Following anion exchange treatment, the solution containing HMO has a pH in the range of 1.5-5.5, preferably 1.5-4. It is not necessary to raise or lower the pH before subjecting the solution to the adsorbent material in step (iv). Furthermore, if the pH is raised at this stage, organic acid impurities—which may still be present in the solution—will become negatively charged and will compete with the negatively charged HMO on the anion exchange material in optional step (vi).
[0048] The adsorbent material in step (iv) is used to remove non-ionic organic components and undissociated molecules and can be a conventional adsorbent material such as activated carbon, but is preferably a cation exchange type material. Compared to the cation exchange material used in step (ii), this cation exchange material preferably has a higher porosity and a lower ionic group density.
[0049] The porosity of the cation exchange material used in step (iv) is preferably in the range of 0.8 to 1.2 ml / g, more preferably 0.9 to 1.1 ml / g, and most preferably 0.95 to 1.05 ml / g. The BET surface area is preferably ≥600 m². 2 / g, more preferably ≥650m 2 / g, or even more preferably ≥670m 2 / g and the optimal value is ≥700m 2 / g.
[0050] The adsorbent material is preferably a styrene / divinylbenzene copolymer matrix, whose hydrophilicity is increased by the presence of sulfonic acid groups. In the method of the present invention, it is used to adsorb components, typically organic components, particularly non-cationic components, and more particularly components that are neutral at the pH of the solution. Compared to adsorbent materials (like activated carbon), this material has the advantage of its inertness in adsorbing acidic oligosaccharides. Surprisingly, the adsorbent material has also been found suitable for removing color from solutions containing HMO. In particular, it has been found to be effective in removing Maillard reaction products and aldol reaction products. The adsorbent material of step (iv) – which is preferably used after the cation exchange (step (ii)) and anion exchange (step (iii)) steps – is also capable of removing (residual) cations. Therefore, the adsorbent material in step (iv) is used to remove (via adsorption) components, especially neutral components.
[0051] Optionally, between steps (iii) and (iv) or after steps (iv) and (v), the acidic solution is subjected to further anion exchange using an anion exchange resin, thereby binding the acidic human milk oligosaccharides to the resin.
[0052] In order to bind HMO, the anions on the anion exchange resin should have a suitable pKa. That is, the pKa of the acid corresponding to the anion should be greater than the pKa of the acid form of the HMO to be purified. For example, most sialic lactose has a pH range up to about 2.9. Therefore, the anion exchange resin preferably contains anion with a corresponding acid pKa greater than this value, more preferably greater than 4, and most preferably greater than 4.5.
[0053] A suitable anion is the hydroxyl group (OH). - ), bicarbonate (HCO3) - ) and monovalent organic acid anions such as acetate. In the most preferred embodiment, the anion is OH-. - .
[0054] The anion exchange resin is preferably a weakly basic anion exchange material because weakly basic anion exchange resins generally have a greater number of functional groups than strong anion exchange resins and are therefore able to bind more HMOs. The weakly basic anion exchange resin is preferably selected from the group consisting of styrene-divinylbenzene anion exchange resins and cross-linked acrylic anion exchange resins, more preferably gel-type styrene-divinylbenzene anion exchange resins and microporous or gel-type cross-linked acrylic anion exchange resins. The resin preferably has tertiary amine functional groups, more preferably dimethylamine functional groups.
[0055] The acidic human milk oligosaccharides were then eluted from the resin using a salt solution, preferably a NaCl solution.
[0056] Following steps (i)-(iv) above—optionally including step (vi) between steps (iii) and (iv) or after step (iv)—the pH of the resulting solution can be adjusted to a value greater than 5, preferably in the range of 5-6. This is used to reduce and / or prevent the hydrolysis of HMO. Preferably, KOH or NaOH, most preferably NaOH, is used to raise the pH.
[0057] This pH adjustment is particularly preferred when step (vi) is not performed.
[0058] Subjecting the crude solution to a single treatment sequence of strong cation exchange, weak anion exchange, adsorption, and optionally anion exchange and elution is usually sufficient. However, if desired, the purified solution can be further processed, for example, further purification and / or concentration. Such further processing preferably includes nanofiltration (NF) and / or reverse osmosis (RO), optionally in combination with percolation. NF or RO treatment is typically used to remove water, thereby concentrating HMO. NF is considered particularly suitable if high flux (requiring less membrane area) is desired. RO, operating at relatively high pressures, has been found to be particularly suitable for obtaining highly concentrated syrups with high HMO content (e.g., 35-50 wt.% HMO content).
[0059] Alternatively or additionally, the purified solution may be subjected to an evaporation step to concentrate the solution, thereby producing a concentrated solution (syrup).
[0060] In a specific embodiment, the concentration step (e.g., by NF, RO, or evaporation) is followed by a sterile microfiltration step to ensure that there are no bacteria or spores in the solution.
[0061] The syrup preferably has an HMO content of at least 25 wt.%, preferably 25-50 wt.%, and particularly 25-35 wt.%.
[0062] If necessary, the HMO obtained by the method of this invention can be subjected to a polishing step using an adsorbent material (such as activated carbon or a charge-modified depth filter). If the purified solution is subjected to a concentration step, the polishing step is typically performed before the concentration step. The polishing step can be used in particular to further reduce or remove organic compounds (such as residual DNA fragments) and / or residual color.
[0063] The solution or syrup produced by the method of the present invention can be subjected to a crystallization step to obtain crystalline HMOs. Suitable crystallization conditions may be based on those known in the art and commonly used for oligosaccharides, or for HMOs of particular interest.
[0064] Alternatively, the solution or syrup can be subjected to a drying step to obtain HMO in powder form. Suitable drying conditions can be based on those known in the art and commonly used for oligosaccharides, or for HMOs of particular interest. Preferred drying steps include spray cooling, spray drying, and freeze drying (lyophilization). Spray drying has yielded particularly good results. The water content of the HMO powder is preferably less than 10 wt.%, more preferably less than 8 wt.%, and even more preferably less than 5 wt.%. Most preferably, based on dry matter (DM), the water content of this powder is in the range of 2% to 4%.
[0065] The method of this invention allows for an HMO yield of 70% or higher (based on the HMO content in the fermentation broth) and an HMO purity of 90 wt.% or higher (based on dry matter). In preferred embodiments, the yield is in the range of 75-99 wt.%, and in specific embodiments it is in the range of 80-97 wt.% (based on the HMO content in the fermentation broth).
[0066] Preferably, 6'-SL is obtained from the fermentation broth in a yield of 70% or higher, more preferably 75% or higher, even more preferably 80% or higher, even more preferably 85% or higher, and most preferably 90% or higher, all based on the 6'-SL content in the fermentation broth.
[0067] Example
[0068] The fermentation broth (20 kg) containing more than 15 g / L 3'-SL was microfiltered to remove bacterial biomass from the liquid. The MF permeate was then subjected to cross-flow ultrafiltration using a 5 kDa ceramic UF membrane (Tami Industries) to remove proteins and residual DNA.
[0069] The UF permeate was then further purified by ion exchange chromatography. In the first column, under H₂O conditions... + Cations are removed using a strong cation exchange resin (styrene-divinylbenzene gel matrix with sulfonate functional groups). The pH of the solution leaving the column is 1.7–1.9. In a second column, cations are removed using a solution containing Cl. - The solution was treated with a weakly basic anion exchange resin (a cross-linked acrylic gel matrix with tertiary amine functional groups) to maintain the pH between 1.7 and 1.9 while reacting with Cl. - Exchange anions. 3'-SL does not bind to the resin under these conditions. The third chromatographic purification step is carried out with an adsorbent resin to remove colorants and other adsorbed impurities without altering the pH of the solution. + A styrene-divinylbenzene copolymer matrix with sulfonic acid functional groups, having a porosity of approximately 1.0 ml / g, an average pore size of 600-900 Å, and a pore size ≥700 μm. 2 / g of surface area.
[0070] The following analytical results demonstrate the purification effect of ion exchange treatment (all quantities are based on dry matter and expressed as a percentage; "nd" indicates "not detected" and means the concentration is below the detection limit of the respective analytical method).
[0071] Components Before IEX After AEX After the adsorbent 3'-SL 67.79 80.26 80.42 phosphorus 1.20 nd nd Sulfates (inorganic) 0.66 nd nd chloride nd 2.63 2.10 sodium 0.67 nd 0.42 Potassium 3.37 nd nd calcium 0.06 nd nd magnesium 0.23 nd nd
[0072] Following the chromatographic steps, the pH of the solution can be increased to the desired level, for example, by adding sodium hydroxide. Residual substances such as chlorides, organic acids, and small-molecule sugars can be further removed by cross-flow nanofiltration, for example, using polymeric polypiperazine or polyamide membranes with a molecular weight cutoff between 150 and 500 Da. By doing so, a significantly higher 3'-SL purity of 88% based on dry matter can be achieved.
Claims
1. A method for purifying acidic human milk oligosaccharides from fermentation broth, the method comprising the following steps: (i) Separate the biomass from the fermentation broth to provide a crude solution; (ii) subject the crude solution to H+ for use + Cation exchange of cation exchange materials in the form of cation exchange, thereby obtaining solutions with a pH range of 1-3; (iii) subject the solution with a pH range of 1-3 to a pH of Cl. - Anion exchange using a weakly basic anion exchange material is employed to obtain a solution with a pH range of 1.5-5.
5. (iv) subject the solution with a pH in the range of 1.5-5.5 to adsorption using an adsorbent material in order to remove neutral organic compounds; (v) Optionally, adjust the pH of the already adsorbed solution to a value in the range of 5-6; (vi) Optionally, the solution is subjected to anion exchange using an anion exchange resin, thereby binding the acidic human milk oligosaccharide to the resin, and then the acidic human milk oligosaccharide is eluted from the resin using a salt solution. This optional step is performed between steps (iii) and (iv) or between steps (iv) and (v). Thus, a purified solution containing the acidic human milk oligosaccharide is obtained.
2. The method according to claim 1, wherein, In step (iii), a solution with a pH in the range of 1.5-4 is obtained.
3. The method according to claim 1 or 2, wherein, The acidic human milk oligosaccharide is selected from the group consisting of: 6'-sialyl lactose, 3'-sialyl lactose, disialialialial-N-tetrasaccharide, 3'-sialic acid-3-fucosylated lactose, and sialyl-N-tetrasaccharide.
4. The method according to claim 3, wherein, The acidic human milk oligosaccharide is selected from 6'-sialyl lactose and 3'-sialyl lactose.
5. The method according to any one of claims 1, 2, and 4, wherein, The cation exchange material in step (ii) is a strong acid cation exchange material.
6. The method according to claim 5, wherein, The strong acid cation exchange material is selected from the group consisting of free gel-type styrene-divinylbenzene cation exchange resins.
7. The method according to claim 6, wherein, The strong acid cation exchange material is a strong acid cation exchange resin having a styrene-divinylbenzene gel-type matrix and sulfonic acid functional groups.
8. The method according to any one of claims 1, 2, 4, 6 and 7, wherein, The weakly basic anion exchange material in step (iii) is selected from the group consisting of: acrylic gel-type matrix with tertiary amine functional groups and styrene-divinylbenzene gel-type matrix.
9. The method according to claim 8, wherein, The weakly basic anion exchange material is selected from the group consisting of: acrylic gel-type matrix with dimethylamine functional group and styrene-divinylbenzene gel-type matrix.
10. The method according to any one of claims 1, 2, 4, 6, 7 and 9, wherein, The adsorbent material in step (iv) is a weak cation exchange material.
11. The method according to claim 10, wherein, The weak cation exchange material is selected from the group consisting of a styrene-divinylbenzene copolymer matrix and sulfonic acid functional groups and has a porosity of 0.8 to 1.2 ml / g and / or ≥ 600 μm. 2 / g of BET surface area.
12. The method according to claim 11, wherein, The weak cation exchange material has a porosity of 0.9 to 1.1 ml / g.
13. The method according to claim 12, wherein, The weak cation exchange material has a porosity of 0.95 to 1.05 ml / g.
14. The method according to any one of claims 11-13, wherein, The weak cation exchange material has a molecular weight of ≥650 m. 2 / g of BET surface area.
15. The method according to claim 14, wherein, The weak cation exchange material has a molecular weight of ≥ 670 m. 2 / g of BET surface area.
16. The method according to claim 15, wherein, The weak cation exchange material has a molecular weight of ≥700 m. 2 / g of BET surface area.
17. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, and 16, wherein, The anion exchange resin in step (vi) is a weakly basic anion exchange resin.
18. The method according to claim 17, wherein, The weakly basic anion exchange resin is selected from the group consisting of: acrylic gel-type matrix with tertiary amine functional groups and styrene-divinylbenzene gel-type matrix.
19. The method according to claim 18, wherein, The weakly basic anion exchange resin is selected from the group consisting of: acrylic gel-type matrix with dimethylamine functional group and styrene-divinylbenzene gel-type matrix.
20. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18 and 19, wherein, Step (i) involves using a membrane with a molecular weight cutoff of 5 kDa or less.
21. The method according to claim 20, wherein, Step (i) involves using a membrane with a molecular weight cutoff of 3 kDa or less.
22. The method according to claim 21, wherein, Step (i) involves using a membrane with a molecular weight cutoff of 3 kDa.
23. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18, 19, 21 and 22, wherein, Step (i) includes a microfiltration step, which is carried out at a temperature in the range of 20°C to 75°C.
24. The method according to claim 23, wherein, The microfiltration step is performed at a temperature ranging from 30°C to 70°C.
25. The method according to claim 24, wherein, The microfiltration step is performed at a temperature in the range of 40°C to 50°C.
26. The method according to claim 24, wherein, The microfiltration step is performed at a temperature in the range of 60°C to 70°C.
27. The method according to claim 23, wherein, The MF permeate is subjected to a cooling step prior to step (ii).
28. The method according to any one of claims 24-26, wherein, The MF permeate is subjected to a cooling step prior to step (ii).
29. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18, 19, 21, 22 and 24-27, wherein, The anion exchange resin in step (vi) is OH- - form.
30. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18, 19, 21, 22 and 24-27, wherein, The method further includes subjecting the purified solution to nanofiltration and / or reverse osmosis.
31. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18, 19, 21, 22 and 24-27, wherein, The purified solution is then subjected to a drying or crystallization step – optionally after one or more additional processing steps.
32. The method according to claim 31, wherein, The purified solution is then subjected to a spray drying step – optionally after one or more additional processing steps.
33. The method according to claim 31, wherein, The human milk oligosaccharide is obtained in powder form and has a water content of less than 10 wt.%.
34. The method according to claim 33, wherein, The human milk oligosaccharide has a water content of less than 8 wt.%.
35. The method according to claim 34, wherein, The human milk oligosaccharide has a water content of less than 5 wt.%.
36. The method according to any one of claims 1, 2, 4, 6, 7, 9, 11-13, 15, 16, 18, 19, 21, 22 and 24-27, wherein, The acidic human milk oligosaccharide is obtained in the form of syrup.
37. A method for producing acidic human milk oligosaccharides, the method comprising producing the acidic human milk oligosaccharides by microbial fermentation in a fermentation broth and purifying the produced acidic human milk oligosaccharides using the method according to any one of claims 1-36.
Citation Information
Patent Citations
Process for isolating sialic acid containing oligosaccharides, and the compositions containing sialic acid containing oligosaccharides obtainable thereby
WO2009113861A2
Isolation and purification of components of whey
WO2010106320A2
Separation of oligosaccharides from fermentation broth
WO2017152918A1
Process for purifying sialylated oligosaccharides
WO2019043029A1
Process for the purification of a neutral human milk oligosaccharide (HMO) from microbial fermentation
WO2019063757A1
